SHR-1703

Phase 3Small molecule

Guangdong Hengrui Pharmaceutical Co., Ltd

SHR-1703 is one of 35 small molecule programs targeting Asthma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AsthmaRecruiting

Granulomatosis With PolyangiitisRecruiting

AsthmaPhase 2

Recruiting

Granulomatosis With PolyangiitisPhase 3

Recruiting

Competition

Competitive Landscape

175 competitors in Asthma

#DrugCompanyPhaseTrials

SHR-1703

Guangdong Hengrui Pharmaceutical Co., Ltd

Phase 3

3 2

Celexa

AbbVie

Preclinical

1 3

Arcoxia

Novartis

Preclinical

—4

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1 5

DUPIXENT

Regeneron

Preclinical

1 6

Paracetamol

GSK

Preclinical

1 7

Blood Withdrawn

Emergent BioSolutions

Preclinical

1 8

Aclidinium Bromide

Atrovent

2 10

Blood Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Recruiting

Asthma

NCT06441812

Q4 2028

Phase 2/3Recruiting

Granulomatosis With Polyangiitis

NCT05979051

Clinical

Trials by Indication[1]

Asthma3 trials

A Study to Evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients With Eosinophil Phenotype

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT05522439·85 enrolled

A Study to Evaluate the Long-term Safety, Pharmacodynamics and Efficacy of SHR-1703 in Eosinophilic Asthma Patients

Recruiting· Guangdong Hengrui Pharmaceutical Co., Ltd logo

Guangdong Hengrui Pharmaceutical Co., Ltd·Phase 2·NCT06441812·200 enrolled

A Trial of SHR-1703 in Asthma

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT05042401·23 enrolled

Adult1 trial

A Trial of SHR-1703 in Healthy Adults

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT04480762·42 enrolled

Trial1 trial

A Trial of SHR-1703 in Healthy Subjects

Terminated·AAtridia Pty Ltd.·Phase 1·NCT04855591·1 enrolled

Granulomatosis with Polyangiitis1 trial

A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA）

Recruiting· Guangdong Hengrui Pharmaceutical Co., Ltd logo

Guangdong Hengrui Pharmaceutical Co., Ltd·Phase 2/3·NCT05979051·166 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for SHR-1703. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SHR-1703 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SHR-1703. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Guangdong Hengrui Pharmaceutical Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Guangdong Hengrui Pharmaceutical Co., Ltd

SHR-1703

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q4 2028

Trials by Indication[1]

Asthma3 trials

Adult1 trial

Trial1 trial

Granulomatosis with Polyangiitis1 trial

References

Drug Info

Quick Facts

Related News